These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 19915710)

  • 1. Impact of Desloratadine on Symptoms and Quality of Life in Subjects with Chronic Idiopathic Urticaria: A Multicenter, Practice-based Study.
    Kim H; Lynde C
    Arch Drug Inf; 2008 Sep; 1(2):63-69. PubMed ID: 19915710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Once-daily desloratadine improves the signs and symptoms of chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled study.
    Ring J; Hein R; Gauger A; Bronsky E; Miller B
    Int J Dermatol; 2001 Jan; 40(1):72-6. PubMed ID: 11277962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of desloratadine in subjects with seasonal allergic rhinitis or chronic urticaria: results of four postmarketing surveillance studies.
    Bachert C; Maurer M
    Clin Drug Investig; 2010; 30(2):109-22. PubMed ID: 20067329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-sedating antihistamines in the treatment of chronic idiopathic urticaria using patient-reported outcomes.
    Grob JJ; Lachapelle JM
    Curr Med Res Opin; 2008 Aug; 24(8):2423-8. PubMed ID: 18651988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of desloratadine in adults with chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled, multicenter trial.
    Ortonne JP; Grob JJ; Auquier P; Dreyfus I
    Am J Clin Dermatol; 2007; 8(1):37-42. PubMed ID: 17298105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Desloratadine for chronic idiopathic urticaria: a review of clinical efficacy.
    DuBuske L
    Am J Clin Dermatol; 2007; 8(5):271-83. PubMed ID: 17902729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Efficacy and Safety of High Dose (10 mg) of Desloratadine (Dazit® 10) in the Treatment of Chronic Spontaneous Urticaria in India: A Phase III, Multicentric, Open-Label, Single-Arm Study.
    Kapadia S; Nageswaramma S; Shah K; Singh A; Mahajan SC; Deshpande A; Chakraborty S; Kar BR; Padmaja P; Bharija SC; Doshi M; Ghadge P; Gabhane M; Dharmadhikari S; Mane A; Mehta S
    Cureus; 2024 Jan; 16(1):e53125. PubMed ID: 38420062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the efficacy of levocetirizine 5 mg and desloratadine 5 mg in chronic idiopathic urticaria patients.
    Potter PC; Kapp A; Maurer M; Guillet G; Jian AM; Hauptmann P; Finlay AY
    Allergy; 2009 Apr; 64(4):596-604. PubMed ID: 19053988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Desloratadine 5 mg once daily improves the quality of life of patients with chronic idiopathic urticaria.
    Lachapelle JM; Decroix J; Henrijean A; Roquet-Gravy PP; De Swerdt A; Boonen H; Lecuyer M; Suys E; Speelman G; Vastesaeger N
    J Eur Acad Dermatol Venereol; 2006 Mar; 20(3):288-92. PubMed ID: 16503889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of desloratadine 5 mg once daily in the treatment of chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled trial.
    Monroe E; Finn A; Patel P; Guerrero R; Ratner P; Bernstein D;
    J Am Acad Dermatol; 2003 Apr; 48(4):535-41. PubMed ID: 12664016
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Desloratadine for chronic idiopathic urticaria].
    Rottem M; Elbirt D; Sthoeger Z;
    Harefuah; 2005 Aug; 144(8):547-53, 599, 598. PubMed ID: 16146151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of desloratadine in chronic idiopathic urticaria in clinical practice: an observational study of 9246 patients.
    Augustin M; Ehrle S
    J Eur Acad Dermatol Venereol; 2009 Mar; 23(3):292-9. PubMed ID: 19438819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized placebo-controlled trial comparing desloratadine and montelukast in monotherapy and desloratadine plus montelukast in combined therapy for chronic idiopathic urticaria.
    Di Lorenzo G; Pacor ML; Mansueto P; Esposito Pellitteri M; Lo Bianco C; Ditta V; Martinelli N; Rini GB
    J Allergy Clin Immunol; 2004 Sep; 114(3):619-25. PubMed ID: 15356567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Levocetirizine for the treatment of allergic rhinitis and chronic idiopathic urticaria in adults and children.
    Singh-Franco D; Ghin HL; Robles GI; Borja-Hart N; Perez A
    Clin Ther; 2009 Aug; 31(8):1664-87. PubMed ID: 19808127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quality of life in adults with chronic idiopathic urticaria receiving desloratadine: a randomized, double-blind, multicentre, placebo-controlled study.
    Grob JJ; Auquier P; Dreyfus I; Ortonne JP
    J Eur Acad Dermatol Venereol; 2008 Jan; 22(1):87-93. PubMed ID: 18181978
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Desloratadine: A preclinical and clinical overview.
    Norman P; Dihlmann A; Rabasseda X
    Drugs Today (Barc); 2001 Apr; 37(4):215-227. PubMed ID: 12768222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The safety and efficacy of desloratadine for the management of allergic disease.
    Berger WE
    Drug Saf; 2005; 28(12):1101-18. PubMed ID: 16329713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Desloratadine: A new, nonsedating, oral antihistamine.
    Geha RS; Meltzer EO
    J Allergy Clin Immunol; 2001 Apr; 107(4):751-62. PubMed ID: 11295678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the efficacy and safety of bilastine 20 mg vs desloratadine 5 mg in seasonal allergic rhinitis patients.
    Bachert C; Kuna P; Sanquer F; Ivan P; Dimitrov V; Gorina MM; van de Heyning P; Loureiro A;
    Allergy; 2009 Jan; 64(1):158-65. PubMed ID: 19132976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Desloratadine.
    McClellan K; Jarvis B
    Drugs; 2001; 61(6):789-96; discussion 797. PubMed ID: 11398910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.